133115-55-6

Basic information

• Product Name: (3-TRIFLUOROMETHOXY-PHENYL)-HYDRAZINE HYDROCHLORIDE
• Synonyms: (3-TRIFLUOROMETHOXY-PHENYL)-HYDRAZINE HYDROCHLORIDE;2-TRIFLUOROMETHYL PHENYLHYDRAZINE HCL;3-trifluoromethoxy phenylhydrazine(HCl);3-Trifluoromethoxy-phenylhydrazine hydrochloride ,98%;3-Trifluoromethoxyphenylhydrazine;Hydrazine, [3-(trifluoromethoxy)phenyl]-, hydrochloride (1:1)
• CAS NO: 133115-55-6
• Molecular Formula: C7H8ClF3N2O
• Molecular Weight: 228.6
• Mol File: 133115-55-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 226.8oC at 760 mmHg
• Flash Point: 91oC
• Appearance: /
• Density: 1.408g/cm3
• Vapor Pressure: 0.0803mmHg at 25°C
• Refractive Index: 1.526
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (3-TRIFLUOROMETHOXY-PHENYL)-HYDRAZINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (3-TRIFLUOROMETHOXY-PHENYL)-HYDRAZINE HYDROCHLORIDE(133115-55-6)
• EPA Substance Registry System: (3-TRIFLUOROMETHOXY-PHENYL)-HYDRAZINE HYDROCHLORIDE(133115-55-6)

Safety Data

• Statements: 20/21/22-36/37/38
• Safety Statements: 26
• Hazardous Substances Data: 133115-55-6(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C7H7F3N2O/c8-7(9,10)13-6-3-1-2-5(4-6)12-11/h1-4,12H,11H2

Upstream product

• 1535-73-5 m-trifluoromethoxyaniline 

Downstream Products

• 1357191-87-7 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-{1-[3-(trifluoromethoxy)phenyl]-1H-pyrazol-5-yl}pyridazin-4(1H)-one 

Relevant articles and documents

HETEROCYCLIC COMPOUND

The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.

THIAZOLYL-DIHYDRO-INDAZOLES

The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a